

Edgar Filing: KIWA BIO-TECH PRODUCTS GROUP CORP - Form 8-K

KIWA BIO-TECH PRODUCTS GROUP CORP

Form 8-K

December 27, 2006

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

December 26, 2006

Date of Report (Date of earliest event reported)

KIWA BIO-TECH PRODUCTS GROUP CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	000-33167	84-0448400
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

415 West Foothill Blvd, Suite 206, Claremont, California 91711-2766

(Address of principal executive offices)

(909) 626-2358

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: KIWA BIO-TECH PRODUCTS GROUP CORP - Form 8-K

Item 1.01 Entry into Material Definitive Agreement

On December 26, 2006, Kiwa Bio-Tech Products (Shandong) Co., Ltd. ("Kiwa SD"), a wholly-owned subsidiary of Kiwa Bio-Tech Products Group Corporation (the "Company"), entered into an Annual Distribution Contract ("the Contract") with Xinjiang Rundi Bio-Tech Co., Ltd. ("Rundi"). Pursuant to the Contract, Kiwa SD appoints Rundi as its exclusive distributor in Xinjiang Uygur Autonomous Region for three years, commencing on January 1, 2007. Rundi has the option to renew the exclusive relationship at the end of the three year term if it meets annual sales objectives of RMB 50 million (approximately US\$6.4 million), however, Kiwa SD has the right to terminate the exclusive relationship if Rundi fails to reach 80% of the annual sales objective. The original contract is in Mandarin. An English translation of the agreement is included as an exhibit to this report.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
10.01	Annual Distribution Contract dated December 26, 2006 between Kiwa Bio-Tech Products (Shandong) Co., Ltd. and Xinjiang Rundi Bio-Tech Co., Ltd.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 26, 2006

By: /s/ Wei Li

Wei Li
Chairman of Board of
Directors and
Chief Executive Officer